Non-alcoholic fatty liver disease in common endocrine disorders

European Journal of Endocrinology

Volumn 169, Issue 2, 2013, Pages

  Hazlehurst, Jonathan M ^a   Tomlinson, Jeremy W ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BROMOCRIPTINE; ESTROGEN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOCORTICOID; GROWTH HORMONE; INSULIN; LIRAGLUTIDE; METFORMIN; PROLACTIN; SOMATOMEDIN C; THYROID HORMONE; VITAMIN D;

CAUSAL ATTRIBUTION; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOCRINE DISEASE; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPOTHYROIDISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THYROID GLAND;

CUSHING SYNDROME; DWARFISM, PITUITARY; FATTY LIVER; HUMANS; HYPOGONADISM; HYPOTHYROIDISM;

EID: 84880946812     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0296     Document Type: Review

References (128)

1. Levene AP & Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012 61 141-152. (doi:10.1111/j.1365-2559.2011.04145.x)
2. Vernon G, Baranova A & Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics 2011 34 274-285. (doi:10.1111/ j.1365-2036.2011.04724.x)
3. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS & Suh DJ. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. Journal of Hepatology 2007 47 239-244. (doi:10.1016/j.jhep.2007.02.007)
4. Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME & Posner MP. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000 69 2410-2415. (doi:10.1097/00007890-200006150-00034)
5. Machado M, Marques-Vidal P & Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. Journal of Hepatology 2006 45 600-606. (doi:10.1016/j.jhep. 2006.06.013)
6. Ong JP, Pitts A & Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. Journal of Hepatology 2008 49 608-612. (doi:10.1016/j.jhep. 2008.06.018)
7. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E & Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: Prospective cohort study. BMJ 2011 343 d6891. (doi:10.1136/bmj.d6891)
8. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006 43 682-689. (doi:10.1002/hep.21103)
9. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K & Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. Journal of Gastroenterology and Hepatology 2009 24 248-254. (doi:10.1111/j.1440-1746. 2008.05640.x)
10. Chung GE, Kim D, Kim W, Yim JY, Park MJ, Kim YJ, Yoon JH & Lee HS. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. Journal of Hepatology 2012 57 150-156. (doi:10.1016/j.jhep.2012.02.027)
11. Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, Yamamoto M, Suda K, Takahashi M, Seo Y et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. European Journal of Endocrinology 2012 167 67-74. (doi:10.1530/ EJE-12-0252)
12. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology 2012 142 711-725.e6. (doi:10.1053/ j.gastro.2012.02.003)
13. Gentile CL, Frye MA & Pagliassotti MJ. Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors 2011 37 8-16. (doi:10.1002/biof.135)
14. Dowman JK, Tomlinson JW & Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010 103 71-83. (doi:10.1093/qjmed/hcp158)
15. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ & Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007 46 1081-1090. (doi:10.1002/hep.21763)
16. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD & Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 2005 115 1343-1351. (doi:10. 1172/JCI200523621)
17. Ibrahim SH, Kohli R & Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. Journal of Pediatric Gastroenterology and Nutrition 2011 53 131-140. (doi:10.1097/MPG. 0b013e31820e82a1)
18. Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F & Gambino R. Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012 56 933-942. (doi:10.1002/hep. 25739)
19. Kern PA, Ranganathan S, Li C, Wood L & Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology. Endocrinology and Metabolism 2001 280 E745-E751.
20. Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z & Serban A. A novel pahtophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. Journal of Physiology and Pharmacology 2012 63 347-353.
21. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC & Pons-Romero F. Gene expression of tumor necrosis factor a and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001 34 1158-1163. (doi:10.1053/jhep. 2001.29628)
22. Polyzos SA, Toulis KA, Goulis DG, Zavos C & Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2011 60 313-326. (doi:10.1016/j.metabol.2010.09.003)
23. Day CP & James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998 114 842-845. (doi:10.1016/S0016-5085(98)70599-2)
24. Jou J, Choi SS & Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Seminars in Liver Disease 2008 28 370-379. (doi:10.1055/s-0028-1091981)
25. Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks JD et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 2008 47 1924-1935. (doi:10.1002/hep.22252)
26. Kim S, Kwon H, Park JH, Cho B, Kim D, Oh SW, Lee CM & Choi HC. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterology 2012 12 69. (doi:10.1186/1471-230X-12- 69)
27. Volzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, Rosskopf D &Wallaschofski H. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. International Journal of Andrology 2010 33 45-53. (doi:10.1111/ j.1365-2605.2009.00953.x)
28. Petta S, Amato MC, Di Marco V, Camma C, Pizzolanti G, Barcellona MR, Cabibi D, Galluzzo A, Sinagra D, Giordano C et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2012 35 238-247. (doi:10.1111/ j.1365-2036.2011.04929.x)
29. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C & Liu K. Serum androgen concentrations in young men: A longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiology, Biomarkers & Prevention 2002 11 (10 Pt 1) 1041-1047.
30. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ & Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebocontrolled Moscow study. Clinical Endocrinology 2010 73 602-612. (doi:10.1111/j.1365-2265.2010.03845.x)
31. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR & Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: A randomised placebo-controlled trial. European Journal of Endocrinology 2012 167 531-541. (doi:10.1530/ EJE-12-0525)
32. Haider A, Gooren LJ, Padungtod P & Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Experimental and Clinical Endocrinology & Diabetes 2010 118 167-171. (doi:10.1055/s-0029- 1202774)
33. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47. (doi:10.1093/humrep/ deh098)
34. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 4237-4245. (doi:10.1210/jc.2006- 0178)
35. Zueff LF, Martins WP, Vieira CS & Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound in Obstetrics & Gynecology 2012 39 341-347. (doi:10.1002/uog. 10084)
36. Kauffman RP, Baker TE, Baker V, KauffmanMM& Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Do androgens play a role? Gynecological Endocrinology 2010 26 39-46. (doi:10.3109/09513590903184084)
37. Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, Piaditis G & Kaltsas G. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertility and Sterility 2010 93 1220-1226. (doi:10.1016/ j.fertnstert.2008.12.008)
38. Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. Journal of Clinical Endocrinology and Metabolism 2012 97 3709-3716. (doi:10.1210/jc.2012-1382)
39. Tang T, Lord JM, Norman RJ, Yasmin E & Balen AH. Insulinsensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2012 5 CD003053.
40. Angelico F, Burattin M, Alessandri C, Del BenM& Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews, 2007.
41. Gangale MF, Miele L, Lanzone A, Sagnella F, Martinez D, Tropea A, Moro F, Morciano A, Ciardulli A, Palla C et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clinical Endocrinology 2011 75 520-527. (doi:10.1111/j.1365-2265.2011.04093.x)
42. Brown AJ, Tendler DA, McMurray RG & Setji TL. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: Beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocrine Practice 2005 11 319-324. (doi:10. 4158/EP.11.5.319)
43. Blouin K, Nadeau M, Perreault M, Veilleux A, Drolet R, Marceau P, Mailloux J, Luu-The V & Tchernof A. Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clinical Endocrinology 2010 72 176-188. (doi:10.1111/j.1365-2265.2009.03645.x)
44. Zhu L, Brown WC, Cai Q, Krust A, Chambon P, McGuinness OP & Stafford JM. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes 2013 62 424-434. (doi:10.2337/db11-1718)
45. Hewitt KN, Pratis K, Jones ME & Simpson ER. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology 2004 145 1842-1848. (doi:10.1210/en.2003-1369)
46. Mu Y, She R, Zhang H, Dong B, Huang C, Lin W, Li D & Li X. Effects of estrogen and androgen deprivation on the progression of non-alcoholic steatohepatitis (NASH) in male Sprague-Dawley rats. Hepatology Research 2009 39 910-920. (doi:10.1111/j. 1872-034X.2009.00512.x)
47. Villa A, Della Torre S, Stell A, Cook J, Brown M & Maggi A. Tetradian oscillation of estrogen receptor a is necessary to prevent liver lipid deposition. PNAS 2012 109 11806-11811. (doi:10.1073/pnas.1205797109)
48. Tian GX, Sun Y, Pang CJ, Tan AH, Gao Y, Zhang HY, Yang XB, Li ZX & Mo ZN. Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obesity Reviews 2012 13 381-387. (doi:10.1111/j.1467-789X.2011. 00978.x)
49. Ogawa Y, Murata Y, Nishioka A, Inomata T & Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998 351 725. (doi:10.1016/S0140-6736(05)78493-2)
50. Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M & Mendez-Sanchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Annals of Hepatology 2010 9 402-409.
51. Florentino G, CotrimHP, FlorentinoA, Padilha C,Medeiros-NetoM, Bragagnol G & Schwingel P. Hormone replacement therapy in menopausal women: Risk factor or protection to nonalcoholic fatty liver disease? Annals of Hepatology 2012 11 147-149.
52. Palin SL, Kumar S, Sturdee DW & Barnett AH. HRT in women with diabetes-review of the effects on glucose and lipid metabolism. Diabetes Research and Clinical Practice 2001 54 67-77. (doi:10.1016/S0168-8227(01)00277- 7)
53. Sites CK, L'Hommedieu GD, Toth MJ, Brochu M, Cooper BC & Fairhurst PA. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: A randomized, double-blind, placebocontrolled trial. Journal of Clinical Endocrinology and Metabolism 2005 90 2701-2707. (doi:10.1210/jc.2004-1479)
54. Takahashi Y. Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver (Review). Endocrine Journal 2012 59 955-962. (doi:10.1507/endocrj.EJ12-0322)
55. Nishizawa H, Takahashi M, Fukuoka H, Iguchi G, Kitazawa R & Takahashi Y. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochemical and Biophysical Research Communications 2012 423 295-300. (doi:10.1016/j.bbrc.2012. 05.115)
56. Xu L, Xu C, Yu C, Miao M, Zhang X, Zhu Z, Ding X & Li Y. Association between serum growth hormone levels and nonalcoholic fatty liver disease: A cross-sectional study. PLoS ONE 2012 7 e44136. (doi:10.1371/journal.pone. 0044136)
57. Koehler E, Swain J, Sanderson S, Krishnan A, Watt K & Charlton M. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: An endocrine signature for advanced fibrosis in obese patients. Liver International 2012 32 279-286. (doi:10.1111/j.1478-3231.2011. 02637.x)
58. Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y, Taura N, Shibata H, Fujimoto M, Toriyama K et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatology International 2007 1 287-294. (doi:10.1007/s12072-007-9007-4)
59. Arturi F, Succurro E, Procopio C, Pedace E, Mannino GC, Lugara M, Procopio T, Andreozzi F, Sciacqua A, Hribal ML et al. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. Journal of Clinical Endocrinology and Metabolism 2011 96 E1640-E1644. (doi:10.1210/ jc.2011-1227)
60. Fusco A, Miele L, D'Uonnolo A, Forgione A, Riccardi L, Cefalo C, Barini A, Bianchi A, Giampietro A, Cimino V et al. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clinical Endocrinology 2012 77 531-536. (doi:10.1111/j.1365-2265.2011.04291.x)
61. Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K & Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 2003 52 914. (doi:10.1136/gut.52.6.914)
62. Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y et al. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 2007 132 938-943. (doi:10.1053/j.gastro.2006.12.024)
63. Gardner CJ, Irwin AJ, Daousi C, McFarlane IA, Joseph F, Bell JD, Thomas EL, Adams VL, Kemp GJ & Cuthbertson DJ. Hepatic steatosis, GH deficiency and the effects of GH replacement: A Liverpool magnetic resonance spectroscopy study. European Journal of Endocrinology 2012 166 993-1002. (doi:10.1530/ EJE-12-0002)
64. Nikkila EA & Pelkonen R. Serum lipids in acromegaly. Metabolism 1975 24 829-838. (doi:10.1016/0026-0495(75)90129-8)
65. Ciresi A, Amato MC, Pizzolanti G & Giordano Galluzzo C. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. Journal of Clinical Endocrinology and Metabolism 2012 97 2907-2915. (doi:10.1210/jc.2012-1518)
66. Madsen M, Krusenstjerna-Hafstrom T, Moller L, Christensen B, Vendelbo MH, Pedersen SB, Frystyk J, Jessen N, Hansen TK, Stodkilde-Jorgensen H et al. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: A randomized clinical trial. Journal of Clinical Endocrinology and Metabolism 2012 97 1227-1235. (doi:10.1210/jc.2011-2681)
67. Hazlehurst JM, Gathercole LL, Nasiri M, Armstrong MJ, Borrows S, Yu J, Wagenmakers AJ, Stewart PM & Tomlinson JW. Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivo. Journal of Clinical Endocrinology and Metabolism 2013 98 1631-1640. (doi:10.1210/jc.2012- 3523)
68. Lemke U, Krones-Herzig A, Berriel Diaz M, Narvekar P, Ziegler A, Vegiopoulos A, Cato AC, Bohl S, Klingmuller U, Screaton RA et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metabolism 2008 8 212-223. (doi:10.1016/ j.cmet.2008.08.001)
69. Li G, Hernandez-Ono A, Crooke RM, Graham MJ & Ginsberg HN. Effects of antisense-mediated inhibition of 11b-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. Journal of Lipid Research 2011 52 971-981. (doi:10.1194/jlr.M013748)
70. Prasad Sakamuri SS, Sukapaka M, Prathipati VK, Nemani H, Putcha UK, Pothana S, Koppala SR, Ponday LR, Acharya V, Veetill GN et al. Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats. PLoS ONE 2012 7 e50216. (doi:10.1371/journal.pone.0050216)
71. Lavery GG, Zielinska AE, Gathercole LL, Hughes B, Semjonous N, Guest P, Saqib K, Sherlock M, Reynolds G, Morgan SA et al. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11b-hydroxysteroid dehydrogenase type 1. Endocrinology 2012 153 3236-3248. (doi:10.1210/en.2012- 1019)
72. Livingstone D, Walker B & Andrew R. Susceptibility to hyperinsulinaemia and fatty liver with loss of 5a-reductase 1 occurs in rats and mice and is not androgen dependent. Endocrine Abstracts 2009 19 136.
73. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP, Besser GM, Grossman AB & Reznek RH. Hepatic steatosis in Cushing's syndrome: A radiological assessment using computed tomography. European Journal of Endocrinology 2003 149 543-548. (doi:10.1530/eje.0.1490543)
74. Zoppini G, Targher G, Venturi C, Zamboni C & Muggeo M. Relationship of nonalcoholic hepatic steatosis to overnight lowdose dexamethasone suppression test in obese individuals. Clinical Endocrinology 2004 61 711-715. (doi:10.1111/j.1365-2265.2004.02154.x)
75. Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L & Falezza G. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clinical Endocrinology 2006 64 337-341. (doi:10.1111/j.1365-2265.2006. 02466.x)
76. Ahmed A, Rabbitt E, Brady T, Brown C, Guest P, Bujalska IJ, Doig C, Newsome PN, Hubscher S, Elias E et al. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS ONE 2012 7 e29531. (doi:10.1371/ journal.pone.0029531)
77. Konopelska S, Kienitz T, Hughes B, Pirlich M, Bauditz J, Lochs H, Strasburger CJ, Stewart PM & Quinkler M. Hepatic 11b-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis. Clinical Endocrinology 2009 70 554-560. (doi:10.1111/j.1365-2265.2008.03358.x)
78. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, Hakkinen AM, Andrew R, Wake DJ, Seckl JR & Walker BR. Body fat distribution and cortisol metabolism in healthy men: Enhanced 5b-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. Journal of Clinical Endocrinology and Metabolism 2003 88 4924-4931. (doi:10.1210/jc.2003-030596)
79. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV et al. The 11-b-hydroxysteroid dehydrogenase type 1 inhibitor INCB 13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010 33 1516-1522. (doi:10.2337/dc09-2315)
80. Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E & Kaufman KD. Effects of an 11b-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes, Obesity & Metabolism 2011 13 498-504. (doi:10.1111/j.1463-1326.2011.01375.x)
81. Flamant F, Baxter JD, Forrest D, Refetoff S, Samuels H, Scanlan TS, Vennstrom B & Samarut J. International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: Thyroid hormone receptors. Pharmacological Reviews 2006 58 705-711. (doi:10.1124/pr. 58.4.3)
82. Klieverik LP, Coomans CP, Endert E, Sauerwein HP, Havekes LM, Voshol PJ, Rensen PC, Romijn JA, Kalsbeek A & Fliers E. Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. Endocrinology 2009 150 5639-5648. (doi:10.1210/en.2009-0297)
83. Nedvidkova J, Haluzik M, Bartak V, Dostalova I, Vlcek P, Racek P, Taus M, Behanova M, Svacina S, Alesci S et al. Changes of noradrenergic activity and lipolysis in the subcutaneous abdominal adipose tissue of hypo-and hyperthyroid patients: An in vivo microdialysis study. Annals of the New York Academy of Sciences 2004 1018 541-549. (doi:10.1196/annals.1296.067)
84. Jornayvaz FR, Lee HY, Jurczak MJ, Alves TC, Guebre-Egziabher F, Guigni BA, Zhang D, Samuel VT, Silva JE & Shulman GI. Thyroid hormone receptor-A gene knockout mice are protected from dietinduced hepatic insulin resistance. Endocrinology 2012 153 583-591. (doi:10.1210/en.2011-1793)
85. Sinha RA, You SH, Zhou J, Siddique MM, Bay BH, Zhu X, Privalsky ML, Cheng SY, Stevens RD, Summers SA et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. Journal of Clinical Investigation 2012 122 2428-2438. (doi:10.1172/JCI60580)
86. Riis AL, Gravholt CH, Djurhuus CB, Norrelund H, Jorgensen JO, Weeke J & Moller N. Elevated regional lipolysis in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2002 87 4747-4753. (doi:10.1210/jc.2002- 020174)
87. Cachefo A, Boucher P, Vidon C, Dusserre E, Diraison F & Beylot M. Hepatic lipogenesis and cholesterol synthesis in hyperthyroid patients. Journal of Clinical Endocrinology and Metabolism 2001 86 5353-5357. (doi:10.1210/jc.86. 11.5353)
88. Ittermann T, Haring R, Wallaschofski H, Baumeister SE, Nauck M, Dorr M, Lerch M, Meyer zu Schwabedissen HE, Rosskopf D & Volzke H. Inverse association between serum free thyroxine levels and hepatic steatosis: Results from the Study of Health in Pomerania. Thyroid 2012 22 568-574. (doi:10.1089/ thy.2011.0279)
89. Xu L, Ma H, Miao M & Li Y. Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: A prospective case-control study. Journal of Hepatology 2012 57 1153-1154. (doi:10.1016/j.jhep.2012.05. 025)
90. Pagadala MR, Zein CO, Dasarathy S, Yerian LM, Lopez R & McCullough AJ. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Digestive Diseases and Sciences 2012 57 528-534. (doi:10.1007/s10620-011-2006-2)
91. Carulli L, Ballestri S, Lonardo A, Lami F, Violi E, Losi L, Bonilauri L, Verrone AM, Odoardi MR, Scaglioni F et al. Is nonalcoholic steatohepatitis associated with a high-thoughnormal thyroid stimulating hormone level and lower cholesterol levels? Internal and Emergency Medicine 2013 8 297-305. (doi:10.1007/s11739-011-0609-4)
92. Gardner CJ, Richardson P, Wong C, Polavarapu N, Kemp GJ & Cuthbertson DJ. Hypothyroidism in a patient with non-alcoholic fatty liver disease. BMJ 2011 342 c7199. (doi:10.1136/bmj. c7199)
93. Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, Linemeyer DL & Erion MD. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009 49 407-417. (doi:10.1002/ hep.22572)
94. Willard FS & Sloop KW. Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Experimental Diabetes Research 2012 2012 470851.
95. Ding X, Saxena NK, Lin S, Gupta NA & Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006 43 173-181. (doi:10.1002/hep.21006)
96. Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, Saxena NK, Sorescu D & Anania FA. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed aWestern diet. American Journal of Physiology. Gastrointestinal and Liver Physiology 2012 302 G225-G235. (doi:10.1152/ajpgi.00274.2011)
97. Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KWet al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS ONE 2012 7 e31394. (doi:10.1371/ journal.pone.0031394)
98. Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 2012 7 e50117. (doi:10.1371/journal.pone.0050117)
99. Armstrong MJ, Houlihan DD, Rowe IA, Clausen WH, Elbrond B, Gough SC, Tomlinson JW & Newsome PN. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program. Alimentary Pharmacology & Therapeutics 2013 37 234-242. (doi:10.1111/apt.12149)
100. Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N & Harrison SA. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series. American Journal of Gastroenterology 2010 105 2707-2709. (doi:10.1038/ajg. 2010.363)
101. Ben-Jonathan N, Hugo ER, Brandebourg TD & LaPensee CR. Focus on prolactin as a metabolic hormone. Trends in Endocrinology and Metabolism 2006 17 110-116. (doi:10.1016/ j.tem.2006.02.005)
102. Davis LM, Pei Z, Trush MA, Cheskin LJ, Contoreggi C, McCullough K, Watkins PA & Moran TH. Bromocriptine reduces steatosis in obese rodent models. Journal of Hepatology 2006 45 439-444. (doi:10.1016/j.jhep.2006.03.019)
103. Berinder K, Nystrom T, Hoybye C, Hall K & Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011 14 199-207. (doi:10.1007/s11102-010-0277-9)
104. Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R & Cakir B. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 2013 In press (doi:10.1007/s12020-012-9857-y)
105. dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC & Gadelha MR. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 2011 19 800-805. (doi:10.1038/oby.2010.150)
106. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE & Kowdley KV. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology 2012 55 1103-1111. (doi:10.1002/hep. 24737)
107. Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, Huang YZ, Honda H, Chen KD,Wang CC et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. Journal of Hepatology 2011 55 415-425. (doi:10.1016/j.jhep.2010.11.028)
108. Rhee EJ, Kim MK, Park SE, Park CY, Baek KH, Lee WY, Kang MI, Park SW, Kim SW & Oh KW. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocrine Journal 2013.
109. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G & Arcaro G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism, and Cardiovascular Diseases 2007 17 517-524. (doi:10.1016/j.numecd. 2006. 04.002)
110. Masuoka HC & Chalasani N. Nonalcoholic fatty liver disease: An emerging threat to obese and diabetic individuals. Annals of the New York Academy of Sciences 2013 1281 106-122. (doi:10.1111/nyas.12016)
111. Doycheva I, Patel N, Peterson M & Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. Journal of Diabetes and its Complications 2013 27 293-300. (doi:10.1016/j. jdiacomp.2012.10.008)
112. El-Serag HB, Tran T & Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004 126 460-468. (doi:10.1053/j.gastro.2003.10.065)
113. Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, Oh KW, Park SW & Lee WY. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: A 4-year longitudinal study. Archives of Medical Research 2013 44 115-120. (doi:10.1016/j.arcmed.2013.01.007)
114. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G & Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007 30 2119-2121. (doi:10.2337/dc07-0349)
115. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C & Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008 51 444-450. (doi:10.1007/ s00125-007-0897-4)
116. Younossi ZM, Gramlich T, Matteoni CA, Boparai N & McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical Gastroenterology and Hepatology 2004 2 262-265. (doi:10.1016/S1542-3565(04) 00014-X)
117. Targher G, Pichiri I, Zoppini G, Trombetta M & Bonora E. Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty liver. Diabetic Medicine 2012 29 220-226. (doi:10.1111/j.1464-5491.2011.03427.x)
118. Targher G, Pichiri I, Zoppini G, Trombetta M & Bonora E. Increased prevalence of cardiovascular disease in type 1 diabetic patients with non-alcoholic fatty liver disease. Journal of Endocrinological Investigation 2012 35 535-540.
119. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L & Bonora E. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. Journal of Hepatology 2010 53 713-718. (doi:10.1016/j.jhep.2010.04. 030)
120. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M & Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012 142 1592-1609. (doi:10.1053/ j.gastro.2012.04.001)
121. Saltiel AR & Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001 414 799-806. (doi:10.1038/414799a)
122. Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, Garcia-Mediavilla MV, Fernandez-Bermejo M, Lozano-Rodriguez T, Vargas-Castrillon J, Buque X, Ochoa B, Aspichueta P et al.Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 2011 60 1394-1402. (doi:10.1136/gut.2010.222844)
123. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E & DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulindependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 1991 72 96-107. (doi:10.1210/jcem-72-1-96)
124. Flannery C, Dufour S, Rabol R, Shulman GI & Petersen KF. Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes 2012 61 2711-2717. (doi:10.2337/ db12-0206)
125. Kawano Y & Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. Journal of Gastroenterology 2013 48 434-441. (doi:10.1007/s00535-013-0758-5)
126. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML & Clore JN. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001 120 1183-1192. (doi:10.1053/ gast.2001.23256)
127. Regnell SE & Lernmark A. Hepatic steatosis in type 1 diabetes. Review of Diabetic Studies 2011 8 454-467. (doi:10.1900/RDS. 2011.8.454)
128. Cleland SJ, Fisher BM, Colhoun HM, Sattar N & Petrie Jr. Insulin resistance in type 1 diabetes: What is 'double diabetes' and what are the risks? Diabetologia 2013 56 1462-1470. (doi:10.1007/ s00125-013-2904-2)